Citius Pharmaceuticals (CTXR) Interest & Investment Income (2014 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Interest & Investment Income came in at $53584.0 in Q1 2026, up 299.49% YoY from $13413.0 in Q1 2025, and up 18.82% on a QoQ basis from $45097.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Interest & Investment Income (2014 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 12 years of Interest & Investment Income data on file, last reported at $53584.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 299.49% year-over-year to $53584.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172741.0 (down 51.77% YoY) and the FY2025 annual result came in at $110081.0, down 85.48% from the prior year.
- Interest & Investment Income improved to $53584.0 in Q1 2026, from $45097.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $336780.0 in Q2 2023 to a low of $13413.0 in Q1 2025.
- A 5-year average of $139035.1 and a median of $117314.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 925.58% — and 2025, when it slumped 92.64%.
- Tracing CTXR's Interest & Investment Income over 5 years: stood at $214549.0 in 2022, then gained by 18.22% to $253638.0 in 2023, then slumped by 91.09% to $22608.0 in 2024, then surged by 99.47% to $45097.0 in 2025, then rose by 18.82% to $53584.0 in 2026.
- The last three Interest & Investment Income figures came in at $53584.0 (Q1 2026), $45097.0 (Q4 2025), and $53423.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 116,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53,584.00 |
| Dec 31, 2025 | 45,097.00 |
| Sep 30, 2025 | 53,423.00 |
| Jun 30, 2025 | 20,637.00 |
| Mar 31, 2025 | 13,413.00 |
| Dec 31, 2024 | 22,608.00 |
| Sep 30, 2024 | 117,314.00 |
| Jun 30, 2024 | 204,843.00 |
| Mar 31, 2024 | 182,205.00 |
| Dec 31, 2023 | 253,638.00 |
| Sep 30, 2023 | 324,813.00 |
| Jun 30, 2023 | 336,780.00 |
| Mar 31, 2023 | 303,275.00 |
| Dec 31, 2022 | 214,549.00 |
| Sep 30, 2022 | 134,826.00 |
| Jun 30, 2022 | 53,020.00 |
| Mar 31, 2022 | 29,571.00 |
| Dec 31, 2021 | 33,982.00 |
| Sep 30, 2021 | 75,601.00 |
| Jun 30, 2021 | 103,413.00 |